These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19110087)

  • 41. Effect of honey on serum cholesterol and lipid values.
    Münstedt K; Hoffmann S; Hauenschild A; Bülte M; von Georgi R; Hackethal A
    J Med Food; 2009 Jun; 12(3):624-8. PubMed ID: 19627212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthetic HDL as a new treatment for atherosclerosis regression: has the time come?
    Conca P; Franceschini G
    Nutr Metab Cardiovasc Dis; 2008 May; 18(4):329-35. PubMed ID: 18378129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Lower LDL and/or raise HDL. In what direction is lipidology moving?].
    Parhofer KG
    MMW Fortschr Med; 2007 May; 149(22):27. PubMed ID: 18069222
    [No Abstract]   [Full Text] [Related]  

  • 45. The use of statins in pediatrics: knowledge base, limitations, and future directions.
    Belay B; Belamarich PF; Tom-Revzon C
    Pediatrics; 2007 Feb; 119(2):370-80. PubMed ID: 17272627
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regression of atherosclerosis demands low LDL targets and raised HDL levels.
    Cardiovasc J Afr; 2008; 19(4):221. PubMed ID: 18776971
    [No Abstract]   [Full Text] [Related]  

  • 47. New evidence supporting aggressive lipid lowering.
    Stein EA
    Postgrad Med; 2003 Apr; 113(4 Suppl):31-40. PubMed ID: 19667621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.
    Preiss D; Sattar N
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Lipid control in diabetic patients in Extremadura (Spain)].
    Roberto Robles N; Barroso S; Marcos G; Sánchez Muñoz-Torrero JF;
    Endocrinol Nutr; 2009 Mar; 56(3):112-7. PubMed ID: 19627723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practicing effective preventive medicine. Pharmacologic interventions in coronary heart disease.
    Eisenberg DA
    Postgrad Med; 2003 Apr; 113(4 Suppl):24-30. PubMed ID: 19667620
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A pilot randomized trial comparing an intensive versus a standard intervention in stable HIV-infected patients with moderate-high cardiovascular risk.
    Masiá M; Bernal E; Padilla S; García N; Escribano JC; Martínez E; Gutiérrez F
    J Antimicrob Chemother; 2009 Sep; 64(3):589-98. PubMed ID: 19625372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical experience with ezetimibe/simvastatin in a Mediterranean population.
    Migdalis I; Efthimiadis A; Pappas S; Alexopoulos D; Vlasserou F; Mikhailidis DP
    Curr Med Res Opin; 2009 Oct; 25(10):2571-6. PubMed ID: 19739939
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.
    Brunzell JD; Davidson M; Furberg CD; Goldberg RB; Howard BV; Stein JH; Witztum JL
    J Am Coll Cardiol; 2008 Apr; 51(15):1512-24. PubMed ID: 18402913
    [No Abstract]   [Full Text] [Related]  

  • 55. The patient at risk: who should we be treating?
    Leitersdorf E
    Br J Clin Pract Suppl; 1994 Dec; (77):24-7. PubMed ID: 19496269
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Towards consistency between guidelines and policy: lipid management--2005.
    Tonkin AM
    Heart Lung Circ; 2005 Dec; 14(4):237-8. PubMed ID: 16360991
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
    Ryan AS; Keske MA; Hoffman JP; Nelson EB
    Am J Ther; 2009; 16(2):183-92. PubMed ID: 19145206
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of quality of dietary fat on serum cholesterol and coronary heart disease: focus on plant sterols and other non-glyceride components.
    Ghafoorunissa
    Natl Med J India; 2009; 22(3):126-32. PubMed ID: 19764688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects.
    Yu BL; Zhao SP
    Med Hypotheses; 2007; 69(1):90-4. PubMed ID: 17239549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.